Compassionate Use of Mifepristone in Brain/Nervous System and Other Cancers
| Status: | Terminated |
|---|---|
| Conditions: | Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 7/1/2018 |
| Start Date: | November 2008 |
| End Date: | December 2015 |
INST 0817: Compassionate Use of Mifepristone
The purpose of this study is to see if mifepristone prevents worsening of your cancer.
Mifepristone is an antiprogesterone agent, a drug which blocks female hormones, that is
commonly used for the termination of pregnancies. It has not been approved by the Food and
Drug Administration for use in the treatment of cancer. It is unlicensed in the United States
for your condition. However, previous work has indicated that mifepristone may be useful due
to how it works. It is being made available for use in the United States for compassionate
use through the Feminist Majority Foundation.
Mifepristone is an antiprogesterone agent, a drug which blocks female hormones, that is
commonly used for the termination of pregnancies. It has not been approved by the Food and
Drug Administration for use in the treatment of cancer. It is unlicensed in the United States
for your condition. However, previous work has indicated that mifepristone may be useful due
to how it works. It is being made available for use in the United States for compassionate
use through the Feminist Majority Foundation.
This is a compassionate use of mifepristone treatment for patients with conditions that could
respond to an antiprogesterone agent, including:
- Meningioma.
- Breast cancer
- Colon Cancer
- Endometrial Stromal Sarcoma
- Bilateral Chronic Central Serous Retinopathy
- Cushing's Syndrome
- Metastatic Adrenocortical Cancer
- Ovarian Cancer
- Other conditions as determined by the attending physicians
respond to an antiprogesterone agent, including:
- Meningioma.
- Breast cancer
- Colon Cancer
- Endometrial Stromal Sarcoma
- Bilateral Chronic Central Serous Retinopathy
- Cushing's Syndrome
- Metastatic Adrenocortical Cancer
- Ovarian Cancer
- Other conditions as determined by the attending physicians
Inclusion Criteria:
- All patients 18 years of age or older.
- Patients must sign an informed consent.
- Patients should be in such a health condition in the opinion of the attending
physician that with the administration of mifepristone benefits may outweigh risks.
Exclusion Criteria:
- Pregnant women or nursing mothers are not eligible for this trial. Patients of child
bearing potential must use adequate contraception.
We found this trial at
1
site
Click here to add this to my saved trials
